Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
OGXI's Cash to Debt is ranked higher than
97% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. OGXI: No Debt )
OGXI' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: No Debt

Equity to Asset 0.62
OGXI's Equity to Asset is ranked higher than
70% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OGXI: 0.62 )
OGXI' s 10-Year Equity to Asset Range
Min: -5.36   Max: 0.95
Current: 0.62

-5.36
0.95
F-Score: 3
Z-Score: -2.40
M-Score: -4.18
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -99.24
OGXI's Operating margin (%) is ranked higher than
72% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. OGXI: -99.24 )
OGXI' s 10-Year Operating margin (%) Range
Min: -48696   Max: 9.64
Current: -99.24

-48696
9.64
Net-margin (%) -90.58
OGXI's Net-margin (%) is ranked higher than
73% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. OGXI: -90.58 )
OGXI' s 10-Year Net-margin (%) Range
Min: -46544   Max: 10.24
Current: -90.58

-46544
10.24
ROE (%) -77.52
OGXI's ROE (%) is ranked higher than
62% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. OGXI: -77.52 )
OGXI' s 10-Year ROE (%) Range
Min: -621.05   Max: 12.27
Current: -77.52

-621.05
12.27
ROA (%) -48.72
OGXI's ROA (%) is ranked higher than
65% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. OGXI: -48.72 )
OGXI' s 10-Year ROA (%) Range
Min: -74.08   Max: 7.33
Current: -48.72

-74.08
7.33
ROC (Joel Greenblatt) (%) -5612.87
OGXI's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. OGXI: -5612.87 )
OGXI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -18547.17   Max: 48.05
Current: -5612.87

-18547.17
48.05
Revenue Growth (%) 1.70
OGXI's Revenue Growth (%) is ranked higher than
80% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. OGXI: 1.70 )
OGXI' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 628.7
Current: 1.7

0
628.7
EBITDA Growth (%) 4.60
OGXI's EBITDA Growth (%) is ranked higher than
82% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. OGXI: 4.60 )
OGXI' s 10-Year EBITDA Growth (%) Range
Min: -74.3   Max: 104.5
Current: 4.6

-74.3
104.5
EPS Growth (%) 6.60
OGXI's EPS Growth (%) is ranked higher than
83% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. OGXI: 6.60 )
OGXI' s 10-Year EPS Growth (%) Range
Min: -74.7   Max: 96.2
Current: 6.6

-74.7
96.2
» OGXI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

OGXI Guru Trades in Q4 2013

Jim Simons 84,800 sh (+62.45%)
» More
Q1 2014

OGXI Guru Trades in Q1 2014

Jim Simons 89,522 sh (+5.57%)
» More
Q2 2014

OGXI Guru Trades in Q2 2014

George Soros 30,800 sh (New)
Jean-Marie Eveillard 574,712 sh (New)
Jim Simons 279,922 sh (+212.69%)
» More
Q3 2014

OGXI Guru Trades in Q3 2014

George Soros Sold Out
Jean-Marie Eveillard 515,512 sh (-10.3%)
Jim Simons 236,415 sh (-15.54%)
» More
» Details

Insider Trades

Latest Guru Trades with OGXI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-09-30 Sold Out $2.77 - $3.64 $ 2.28-28%0
Jean-Marie Eveillard 2014-06-30 New Buy0.01%$3.35 - $11.5 $ 2.28-59%574712
George Soros 2014-06-30 New Buy$3.35 - $11.5 $ 2.28-59%30800
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.25
OGXI's P/B is ranked higher than
96% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. OGXI: 1.25 )
OGXI' s 10-Year P/B Range
Min: 0.3   Max: 9
Current: 1.25

0.3
9
P/S 1.18
OGXI's P/S is ranked higher than
98% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. OGXI: 1.18 )
OGXI' s 10-Year P/S Range
Min: 0.59   Max: 4799.97
Current: 1.18

0.59
4799.97
EV-to-EBIT 0.18
OGXI's EV-to-EBIT is ranked higher than
100% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. OGXI: 0.18 )
OGXI' s 10-Year EV-to-EBIT Range
Min: -340.1   Max: 15.6
Current: 0.18

-340.1
15.6
Current Ratio 2.93
OGXI's Current Ratio is ranked higher than
65% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. OGXI: 2.93 )
OGXI' s 10-Year Current Ratio Range
Min: 0.05   Max: 18.91
Current: 2.93

0.05
18.91
Quick Ratio 2.93
OGXI's Quick Ratio is ranked higher than
66% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. OGXI: 2.93 )
OGXI' s 10-Year Quick Ratio Range
Min: 0.05   Max: 18.91
Current: 2.93

0.05
18.91

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.60
OGXI's Price/Net Cash is ranked higher than
98% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. OGXI: 1.60 )
OGXI' s 10-Year Price/Net Cash Range
Min: 0.59   Max: 847.67
Current: 1.6

0.59
847.67
Price/Net Current Asset Value 1.43
OGXI's Price/Net Current Asset Value is ranked higher than
99% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. OGXI: 1.43 )
OGXI' s 10-Year Price/Net Current Asset Value Range
Min: 0.58   Max: 847.67
Current: 1.43

0.58
847.67
Price/Tangible Book 1.24
OGXI's Price/Tangible Book is ranked higher than
97% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. OGXI: 1.24 )
OGXI' s 10-Year Price/Tangible Book Range
Min: 0.47   Max: 30.82
Current: 1.24

0.47
30.82
Price/Median PS Value 0.14
OGXI's Price/Median PS Value is ranked higher than
99% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. OGXI: 0.14 )
OGXI' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 351.69
Current: 0.14

0.09
351.69
Earnings Yield (Greenblatt) 555.60
OGXI's Earnings Yield (Greenblatt) is ranked higher than
100% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. OGXI: 555.60 )
OGXI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 6.4   Max: 1723.7
Current: 555.6

6.4
1723.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SP4A.Germany,
OncoGenex Pharmaceuticals Inc was incorporated in California in October 1991 and reorganized as a Delaware corporation in March 1995. The Company is a biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. It has three product candidates in pipeline: custirsen, apatorsen and OGX-225 of which custirsen is in Phase 3 clinical-stage and apatorsen is in Phase 2 clinical-stage. Custirsen is being evaluated in three phase 3 trials; two in patients with prostate cancer and one in patients with non-small cell lung cancer. A patorsen is designed to inhibit production of heat shock protein 27, a cell-survival protein expressed in many types of cancers including bladder, non-small cell lung, pancreatic, prostate and breast cancers. OGX-225 is designed to inhibit the production of Insulin Growth Factor Binding Proteins -2 and -5, two proteins that affect the growth of cancer cells when overexpressed, observed in many human cancers, including prostate, breast, colorectal, non-small cell lung, glioblastoma, acute myeloid leukemia, acute lymphoblastic leukemia, neuroblastoma, and melanoma. In order to undertake clinical trials and to produce and market products for human use, the Company is subject to mandatory procedures and safety standards established by the FDA in the United States and by comparable agencies in other countries. The Company owns eight trademarks registered in the United States, namely ONCOGENEX, ORCA, Spruce, Rainier, ORCA and design, Pacific and design, Borealis-1 and design, and the helical totem design element that accompanies the clinical trial trademarked identifiers. In Canada, it has OncoGenex registered, and has corresponding Canadian trademark applications pending for the United States registrations. Additional trade-marks in use but still pending registration in both the United States and Canada trademark offices are Borealis-2, Cedar, and the OncoGenex script design.
» More Articles for OGXI

Headlines

Articles On GuruFocus.com
George Soros Had A Mixed Day On The Market Oct 30 2014 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 1 Jan 06 2011 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 5 Dec 03 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 5 Nov 17 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 5 Nov 02 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) Aug 05 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q/A) May 10 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) May 06 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) Nov 05 2009 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) Aug 06 2009 

More From Our Partners
OncoGenex's Pancreatic Cancer Study Fully Enrolled - Analyst Blog Dec 17 2014 - ZACKS

More From Other Websites
OncoGenex Announces Completion of Patient Enrollment in the Rainier™ Clinical Trial Evaluating... Dec 16 2014
OncoGenex Announces Completion of Patient Enrollment in the Rainier™ Clinical Trial Evaluating... Dec 16 2014
OncoGenex Announces Completion of Patient Enrollment in the Rainier™ Clinical Trial Evaluating... Dec 16 2014
5 Stocks Poised for Breakouts: Trulia and More Dec 12 2014
OncoGenex Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference Nov 17 2014
OncoGenex Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference Nov 17 2014
OncoGenex Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference Nov 17 2014
10-Q for OncoGenex Pharmaceuticals, Inc. Nov 01 2014
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014 Oct 30 2014
OncoGenex Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Oct 30 2014
ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Oct 30 2014
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014 Oct 30 2014
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014 Oct 30 2014
Q3 2014 OncoGenex Pharmaceuticals Inc Earnings Release - After Market Close Oct 30 2014
Some Of Soros' Stocks Surged Today, While Others Soured Oct 29 2014
OncoGenex to Report Financial Results for Third Quarter 2014 on October 30, 2014 Oct 16 2014
OncoGenex to Report Financial Results for Third Quarter 2014 on October 30, 2014 Oct 16 2014
OncoGenex to Report Financial Results for Third Quarter 2014 on October 30, 2014 Oct 16 2014
5 Stocks Under $10 to Trade for Breakouts Sep 18 2014
OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in... Sep 16 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK